Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Stop SINE

With $48M, Karyopharm looks to advance cancer compound through pivotal trials

Stop SINE

Karyopharm Therapeutics Inc. hopes to advance lead compound KPT-330 through pivotal trials for at least two cancer indications with funds from last week's $48.2 million series B round.

An undisclosed

Read the full 302 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE